Xencor reported Q3 2022 financial results, with total revenue of $27.3 million and a net loss of $32.8 million, or $(0.55) per share. The company's cash, cash equivalents, receivables, and marketable debt securities totaled $654.6 million as of September 30, 2022. Xencor also announced initial results from its Phase 1a study of XmAb564, which showed promising tolerability and T-cell expansion.